Recent News
Nov 10, 2023
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
Events and presentations
Dec 05, 2023
JMP Securities Hematology and Oncology Summit
Nov 15, 2023
Stifel Healthcare Conference
Our commitment to patients
At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.
read onMeet the Blue Crew
Meet the Blue Crew
Pablo Sierra, Associate Medical Director, Iberia & UK, Global Medical Affairs
I am part of the International Medical Affairs Team, responsible for leading the Medical Affairs function on a national level across Spain, Portugal and the UK with a growing team of highly talented people. Our goal is to ensure timely patient access to our transformative medicines by being the bridge between the company and the external scientific/medical community, from early stages of clinical development to commercialization and beyond.
Read onWe aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.
read on“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Kate Haviland, Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Kate Haviland, Chief Executive Officer
Dare to be different
We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.
read on